Brind.
  1. A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.

Glucotrack, Inc. submitted an Investigational Device Exemption to the FDA and appointed a new Medical Director.

3 reports, 1 independent Updated Aug 15
Gone quiet
Reports
3
Developments
2
Repetition
33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Glucotrack, Inc. submitted an Investigational Device Exemption to the FDA and appointed a new Medical Director.

Who's involved

What this event is mainly about
FDA

How it developed

Newest first. Tap a step to see who reported it.
  1. Glucotrack filed an IDE with the FDA and announced a new Medical Director.1 source
  2. Glucotrack is preparing for a US pilot study and exhibiting at the ADCES Annual Meeting.1 source

Keep exploring

Part of

A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.

Also in this story

All 83 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • GlobeNewswireGlucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights On track to implant first patients in long-term, multicenter feasibility study of the fully implantable contin
  • GlobeNewswireGlucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology Experienced cardiac electrophysiologist joins Glucotrack’s growing clinical advisory team as th
  • GlobeNewswireGlucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting Company to present endocrinologist perspectives on implantable CBGM technology as it advances towar